neurology

News

Roche has added a phase 3 trial of trontinemab, hoping to show it can delay or prevent progression to Alzheimer's symptoms in preclinical patients.

Market Access

What were the major themes to come out of BIO Boston 2025? Despite global events in the background, a fair amount of positivity.

R&D

Dr Bruce Leuchter, CEO of GRIN Therapeutics and Neurvati Neurosciences, discusses the companies GRIN-NDD work with pharmaphorum.

News

INmune Bio's bid to develop an Alzheimer's drug with a new mechanism of action has been dented, but the company remains upbeat.

News

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

News

Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.